AXIM Biotechnologies, Inc.
AXIM · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $108 | $0 | $116 | $106 |
| Gross Profit | -$108 | $0 | -$116 | -$106 |
| % Margin | – | – | – | – |
| R&D Expenses | $45 | $45 | $10 | $10 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $137 | $115 | $243 | $302 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $108 | $3 | $3 |
| Operating Expenses | $182 | $269 | $256 | $314 |
| Operating Income | -$290 | -$269 | -$372 | -$420 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $426 | $34 | -$45 | -$113 |
| Pre-Tax Income | $136 | -$234 | -$417 | -$534 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $136 | -$234 | -$417 | -$534 |
| % Margin | – | – | – | – |
| EPS | 0 | -0.001 | -0.001 | -0.002 |
| % Growth | 157.1% | 46.2% | 27.8% | – |
| EPS Diluted | 0 | -0.001 | -0.001 | -0.002 |
| Weighted Avg Shares Out | 332,761 | 332,761 | 318,895 | 302,895 |
| Weighted Avg Shares Out Dil | 332,761 | 332,761 | 318,895 | 302,895 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $84 | $73 | $98 | $76 |
| Depreciation & Amortization | $108 | $108 | $110 | $106 |
| EBITDA | $328 | -$53 | -$214 | -$352 |
| % Margin | – | – | – | – |